Theraclone Sciences, Inc. - Product Pipeline Review - 2014

Published: Sep, 2014 | Pages: 41 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Theraclone Sciences, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Theraclone Sciences, Inc. - Product Pipeline Review - 2014', provides an overview of the Theraclone Sciences, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Theraclone Sciences, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Theraclone Sciences, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Theraclone Sciences, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Theraclone Sciences, Inc.'s pipeline products

Reasons to buy

- Evaluate Theraclone Sciences, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Theraclone Sciences, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Theraclone Sciences, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Theraclone Sciences, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Theraclone Sciences, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Theraclone Sciences, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Theraclone Sciences, Inc. Snapshot 5
Theraclone Sciences, Inc. Overview 5
Key Information 5
Key Facts 5
Theraclone Sciences, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Theraclone Sciences, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
Theraclone Sciences, Inc. - Pipeline Products Glance 13
Theraclone Sciences, Inc. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Theraclone Sciences, Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Theraclone Sciences, Inc. - Drug Profiles 16
TCN-032 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
TCN-202 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Monoclonal Antibodies to Target Hemagglutinin for Seasonal Influenza and Pandemic Influenza 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
PGT-121 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Monoclonal Antibodies for Breast Cancer 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Monoclonal Antibodies to Target GM-CSF 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Monoclonal Antibodies to Target Interferon-alfa 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Monoclonal Antibody for Asthma, COPD and Rhinovirus Infections 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Monoclonal Antibody for Cancer 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Monoclonal Antibody for Cancers Associated Infectious Diseases 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Monoclonal Antibody for Klebsiella Pneumoniae Infections 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Monoclonal Antibody for Undisclosed Target 1 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Monoclonal Antibody for Undisclosed Target 2 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Theraclone Sciences, Inc. - Pipeline Analysis 30
Theraclone Sciences, Inc. - Pipeline Products by Target 30
Theraclone Sciences, Inc. - Pipeline Products by Route of Administration 31
Theraclone Sciences, Inc. - Pipeline Products by Molecule Type 32
Theraclone Sciences, Inc. - Pipeline Products by Mechanism of Action 33
Theraclone Sciences, Inc. - Recent Pipeline Updates 34
Theraclone Sciences, Inc. - Dormant Projects 38
Theraclone Sciences, Inc. - Locations And Subsidiaries 39
Head Office 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Tables
Theraclone Sciences, Inc., Key Information 5
Theraclone Sciences, Inc., Key Facts 5
Theraclone Sciences, Inc. - Pipeline by Indication, 2014 8
Theraclone Sciences, Inc. - Pipeline by Stage of Development, 2014 9
Theraclone Sciences, Inc. - Monotherapy Products in Pipeline, 2014 10
Theraclone Sciences, Inc. - Out-Licensed Products in Pipeline, 2014 11
Theraclone Sciences, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 12
Theraclone Sciences, Inc. - Phase II, 2014 13
Theraclone Sciences, Inc. - Preclinical, 2014 14
Theraclone Sciences, Inc. - Discovery, 2014 15
Theraclone Sciences, Inc. - Pipeline by Target, 2014 30
Theraclone Sciences, Inc. - Pipeline by Route of Administration, 2014 31
Theraclone Sciences, Inc. - Pipeline by Molecule Type, 2014 32
Theraclone Sciences, Inc. - Pipeline Products by Mechanism of Action, 2014 33
Theraclone Sciences, Inc. - Recent Pipeline Updates, 2014 34
Theraclone Sciences, Inc. - Dormant Developmental Projects,2014 38